Cardiovascular outcomes across GLP-1/GIP agonists in a large, diverse real-world cohort: the INCRETIN-CV study

29 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Cardiometabolic pharmacotherapy for cardiovascular risk Antidiabetic Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology